Diagnosis and appropriate treatment of multidrug-resistant tuberculosis (MDR-TB), as well as extensively drug-resistant-TB (XDR-TB) represent major challenges to TB control. During recent years significant progress in the development of rapid molecular diagnostic techniques for TB and drug resistant TB detection has been achieved with their implementation in national TB programs for accelerated TB and MDR-TB detection. After the pipeline of new and effective anti-tuberculosis drugs has been dry for over 50 years recently discovered drugs have been introduced for use in clinical practice. New WHO guidelines on treatment of MDR-TB, including diagnostic algorithms, regimen composition, patient’s management update and new drug introduction policies have been launched.

The WHO Collaborating Centre for Research and Training in Management of MDR-TB (WHO CC) was established in 2004 with the objective to provide high quality, evidence based training and education on different aspects in controlling MDR-TB in line with the latest developments, evidence and WHO strategies. Training programs are structured combining latest scientific developments with practical aspects of innovations in treatment and management of DR-TB.

<table>
<thead>
<tr>
<th>Time</th>
<th>Course</th>
<th>Registration</th>
</tr>
</thead>
<tbody>
<tr>
<td>27.03.— 05.04.2017.</td>
<td>Advanced course on clinical management of DR-TB (Russian language)</td>
<td>27.02.2017</td>
</tr>
<tr>
<td>03.04.— 07.04.2017.</td>
<td>Introduction of new and re-purposed drugs for DR-TB under program conditions (Russian language)</td>
<td>27.02.2017.</td>
</tr>
<tr>
<td>21.08.— 30.08. 2017</td>
<td>Advanced course on clinical management of DR-TB (Russian language)</td>
<td>03.07.2017.</td>
</tr>
</tbody>
</table>
Advanced course on clinical management of DR-TB

- Global and regional epidemiology of TB, MDR-TB, XDR-TB and TB/HIV.
- WHO recommended END TB strategy.
- The main interventions to prevent development and spread of DR-TB.
- WHO policy guidance on TB diagnostics; progress in diagnostics of MDR-TB.
- Effective strategies for case finding and diagnosis of all forms of TB; European TB Laboratory Initiative (ELI) proposed Laboratory Diagnostic Algorithm tailored for the needs and capacities of the WHO European Region.
- New and repurposed drugs in treatment of TB: WHO policy recommendations.
- Treatment regimen design, options with and without new and re-purposed drugs for patients with pre-XDR, XDR-TB or MDR-TB.
- Management of TB drug side effects, Drug toxicity in treatment of TB/HIV.
- Active drug safety monitoring and management (aDSM).
- Monitoring of treatment effectiveness and outcome evaluation of TB and MDR-TB patients.
- Treatment of MDR-TB in special situations including children, TB/HIV coinfection.
- Adjuvant therapies in M/XDR-TB management: nutrition, surgery, rehabilitation.
- Fundamentals of infection control.
- Management of failures and chronic patients, role of palliative care.
- Patient centered approach in TB care including ethical issues, human rights.
- Management of TB and MDR-TB patients in outpatient treatment settings.

Duration: 9 working days (from Monday to Wednesday, including Saturday)
Language: Russian/English
Training fee: 2370 EUR including training materials, site visit, local transfers, catering during working hours/working days, social event, visa support, hotel accommodation for 11 nights, reduced per diem (30 EUR * 11 days)

Introduction of new and re-purposed drugs for DR-TB under program conditions

- Global and regional epidemiology of TB, MDR-TB, XDR-TB and TB/HIV.
- WHO-recommended END TB strategy.
- Key principles for rational introduction of new TB drugs and regimens in countries.
- Global perspective and lessons learned in use of new and re-purposed anti TB drugs.
- New and re-purposed drug information and evidence for use for MDR-TB.
- Country implementation plans and preparedness.
- Diagnosis of MDR-TB for treatment with new and re-purposed drugs.
- Use of recently recommended WHO rapid molecular tests and initiation of shorter treatment regiments; Proposed diagnostic algorithm by the European TB Laboratory Initiative for use in the WHO European Region.
- The clinical issues in new drug introduction, regimen composition and design.
- Monitoring and evaluation requirements using new and re-purposed drugs, length of therapy with new drugs.
- New and re-purposed drug use in special populations, drug interactions.
- Monitoring and management of adverse events.
- Main safety considerations. Active drug safety monitoring and management (aDSM).
- Adherence support, ethical considerations and informed consent, how to talk with patients about new and re-purposed drugs.
- Adjuvant therapies, role of surgery using new and re-purposed drugs.

Duration: 5 working days (from Monday to Friday)
Language: Russian
Training fee: 1520 EUR including training materials, site visit, local transfers, catering during working hours/working days, social event, visa support, hotel accommodation for 6 nights, reduced per diem (30 EUR * 6 days)

Contact information
for program details, requests: Dr. Liga Kuksa, liga.kuksa@aslimnica.lv
for registration, visa, logistic issues: Ms. Liga Rusmane, e-mail: liga@ltbf.lv